Mr. Hugh MacNaught reports

VENTRIPOINT PARTNERS WITH FOURNEL ADVISORY

Ventripoint Diagnostics Ltd. has entered into an advisory agreement with Fournel Advisory to provide the company with financial advisory, business development, and merger-and-acquisition services for one year to accelerate the commercialization of Ventripoint's artificial-intelligence-powered, heart-scanning technology. Under the terms of the agreement, the company shall pay a cash fee and provide Fournel an option to purchase 265,000 common shares at the market price on June 11, 2025, of 11 cents, subject to TSX Venture Exchange approval.

Strategic advisory

Fournel Advisory is a Paris-based consulting firm dedicated to supporting entrepreneurs and business leaders across small-capitalization and mid-capitalization markets. Since 2013, Fournel has specialized in M&A advisory, fundraising, and special situations, both in France and internationally. With a strong focus on the health care and life science sectors, it brings tailored, high-impact advice to clients at every stage of their growth. It is supported by the Fournel Advisory life sciences scientific committee -- referred to as its KOL network -- comprising leading figures from academia, biotechnology, life sciences and finance worldwide. This unique resource allows Fournel to identify new trends, provide strategic insights into value creation and support critical fundraising documentation.

Fournel Advisory has completed more than 50 transactions since its inception and currently supports around 30 active mandates, ranging from biotech and medtech to pharma and medical devices. It is stage-agnostic, helping start-ups and growth companies alike, from early development through late-stage expansion. Seventy per cent of Fournel's client base and investor relationships are international, especially across North America (United States and Canada) and Europe.

Founded by Pierre-Jean Esmieu Fournel, a former HEC graduate and investment banker at Societe Generale (New York, South Africa and United Kingdom), and later chief financial officer and vice-president of business development at Ethypharm, where he led a $135-million fundraising in a turnaround situation, Fournel Advisory was born out of first-hand experience in the challenges -- and the promise -- of the biotech and pharma worlds. Fournel is passionate about enabling pioneering companies to achieve their ambitions by providing financial expertise, strategic advice and access to a global network of investors and partners.

"Ventripoint is excited by the opportunity to work with the Fournel Advisory team," stated Ventripoint president and chief executive officer Hugh MacNaught. "Their experience in the health care sector and extensive network will be invaluable in accelerating Ventripoint's growth and supporting the true value of the company."

Commenting on the agreement, Mr. Fournel said: "We are delighted to partner with Ventripoint, a company at the intersection of AI and cardiac imaging, whose technology has the potential to reshape cardiovascular diagnostics. At Fournel Advisory, we strongly believe in the power of health care innovation, and we are committed to leveraging our global network and financial expertise to support Ventripoint's growth and long-term success."

With its proprietary VMS+ platform, Ventripoint is revolutionizing cardiac diagnostics by delivering a powerful artificial-intelligence-driven solution that enhances echocardiography and serves as an affordable and more accessible alternative to traditional MRI scans. Following recent regulatory milestones, Ventripoint is primed to expand its presence in key markets and drive widespread adoption.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of artificial intelligence to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.